| Literature DB >> 28331078 |
Gareth J Jones1, Mick Coad2, Bhagwati Khatri2, Javier Bezos3,4, Natalie A Parlane5, Bryce M Buddle5, Bernardo Villarreal-Ramos2, R Glyn Hewinson2, H Martin Vordermeier2.
Abstract
Mycobacterium bovis BCG vaccination sensitizes cattle to bovine tuberculin, which compromises the use of the current bovine tuberculosis (TB) surveillance tests. Although the performance of a blood test (that utilizes antigens expressed by Mycobacterium bovis but not by BCG) capable of discriminating infected from vaccinated animals (DIVA interferon gamma test [DIT]) has been evaluated in naturally infected TB field reactors, there is a need to perform similar analysis in a BCG-vaccinated M. bovis-infected population. Furthermore, we explored different scenarios under which a DIT may be implemented alongside BCG vaccination: (i) serial testing to resolve potential false-positive skin test results or (ii) a standalone test to replace the single intradermal comparative cervical tuberculin (SICCT) skin test. Our results demonstrated significantly better relative test sensitivity when the DIT was evaluated in a serial test scenario. Direct comparison of pre- and post-skin test blood samples revealed that the SICCT test induced significant boosting of the gamma interferon response in M. bovis-infected animals to both the ESAT-6-CFP-10 and Rv3615c peptide cocktails that comprise the DIT, which persisted for the ESAT-6-CFP-10 reagent for at least 14 days. Importantly, no similar boosting effects were observed in noninfected BCG vaccinates, suggesting that DIVA blood testing after a recent skin test would have minimal impact on test specificity. © Crown copyright 2017.Entities:
Keywords: DIVA; Mycobacterium bovis; blood test; bovine tuberculosis; gamma interferon; tuberculin skin test
Mesh:
Substances:
Year: 2017 PMID: 28331078 PMCID: PMC5424240 DOI: 10.1128/CVI.00551-16
Source DB: PubMed Journal: Clin Vaccine Immunol ISSN: 1556-679X